Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

68.51 +0.81 (+1.20%)
Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
84 85 Next >
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Via The Motley Fool
Down 60%, Is This Growth Stock Too Cheap to Ignore?
Via The Motley Fool
Novo Nordisk's FDA Submission For Obesity Pill Gets Retail Traders Buzzing Amid Fierce Eli Lilly Rivalry
The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed successful results. 
Via Stocktwits
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Via The Motley Fool
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Via The Motley Fool
Eli Lilly's Experimental Weight Loss Pill Succeeded in Its First Pivotal Trial. Is It Time to Buy?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength. 
Via Benzinga
Topics ETFs
Where Will Eli Lilly Be in 5 Years?
Via The Motley Fool
Netflix, UnitedHealth, Novo Nordisk, Tesla And Trump Media: Why These 5 Stocks Are On Investors' Radars Today
Wall Street experienced a resurgence in risk appetite on Thursday as optimism grew around trade negotiations. 
Via Benzinga
Topics Government
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035. 
Via Benzinga
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
Analyst downgrades Novo Nordisk, citing Eli Lilly's rising dominance and weak competitive outlook for 2025. 
Via Benzinga
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential
Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by... 
Via Benzinga
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
Mark Cuban Says This Trump Healthcare Order 'Could Save Hundreds Of Billions'
Billionaire entrepreneur Mark Cuban has expressed support for President Donald Trump's 2025 healthcare executive order, emphasizing its potential to reform the role of Pharmacy Benefit Managers (PBMs)... 
Via Benzinga
Topics Government
This Twin Disc Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Eli Lilly’s Weight Loss Pill Succeeds In Phase 3 Trials On Type-2 Diabetes Patients
The company says orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist to successfully complete a Phase 3 trial. 
Via Stocktwits
Topics Economy Government Stocks
Eli Lilly Stock Rockets On Weight-Loss Pill Progress
Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles. 
Via Investor's Business Daily
Topics Government
While growth is established for NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), the stock's valuation remains reasonable.
Discover NOVO-NORDISK A/S-SPONS ADR, an undervalued growth gem. NYSE:NVO is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
This Microsoft Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
Viking Therapeutics Stock Pops But Struggles to Hold Gains
VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington 
Via MarketBeat
Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts
FDA and Novo Nordisk warn about counterfeit Ozempic in the U.S. with fake serial numbers, posing risks due to unknown contents and unverified sterility. 
Via Benzinga
Topics Economy
Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models
Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising obesity treatment potential. 
Via Benzinga
Eli Lilly's Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move Up Wegovy Launch
Mounjaro's launch in India sparks a surge in patient demand as Eli Lilly gains a market edge ahead of Novo Nordisk and upcoming generic competition. 
Via Benzinga
Novo Nordisk Warns Against Counterfeit Ozempic In US: Retail’s Unmoved
The company said the seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits, 51746517. 
Via Stocktwits
Topics Economy
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Pfizer bows, but is not entirely out of the GLP-1 race. 
Via The Motley Fool
Recent Filing Shows That Rep. Scott Franklin Bought Over $16K Worth of Novo Nordisk Stock
Via Benzinga
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
Is Novo Nordisk Gaining or Losing Market Support?
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
84 85 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.